Dan Wagner

Mr. Wagner is responsible for evaluating investment opportunities, structuring investments and monitoring portfolio companies through active board participation. He has led or assisted with Connecticut Innovation’s (CI) investments in AxioMx (acquired by Abcam); Affomix (acquired by Illumina); CyVek (acquired by Bio-Techne); Cara Therapeutics (NASDAQ: CARA); HistoRx (acquired by Genoptix); Melinta Therapeutics, formerly Rib-X (NASDAQ: MLNT); RemoteReality (acquired by RTI); Biohaven Pharmaceuticals (NYSE: BHVN); and Arvinas (NASDAQ: ARVN). Mr. Wagner contributes to CI’s expertise in biotech with more than 10 years in the industry. He was previously employed CuraGen Corporation. Where he held a variety of scientific and operational management positions in research and development, technology assessment and implementation of next-generation scientific technologies that supported CuraGen’s growth from a genomic and proteomic platform company into a biopharmaceutical firm.